DESPITE significant advances in prostate imaging in recent years, notably the emergence of multiparametric magnetic resonance imaging (MRI) and molecular imaging, biopsy remains central to prostate cancer diagnosis. Over 2 million prostate biopsies are performed annually worldwide, and these are performed via the transrectal or transperineal route.
Traditional transrectal ultrasound-guided prostate biopsies (TRUSB) involve an...
A new report entitled ‘Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit – the ‘Fry‐Turnbull’ effect,’ published in the British Journal of Urology International (BJUI,) highlights the effects of celebrity endorsement of cancer screening and the importance this has in raising public awareness.
Following Stephen Fry and Bill Turnbull’s prostate cancer diagnoses, both celebrities spoke...
A new research paper recently published in the peer-reviewed urology journal, BJU International, gives further weight to the eradication of the transrectal (TR) prostate biopsy from the prostate cancer pathway.
The study, in which the authors evaluated nearly half a million prostate biopsies in the NHS over the last decade, gives sufficient evidence for the distinct advantages of the transperineal (TP) route over the TR route i...
A new study published in the American Urological Association Journal of Urology adds the largest cohort data to the body of literature for MRI in active surveillance of prostate cancer. The study, funded by the Canary Foundation, investigated the ability of prostate MRI to detect Gleason Grade Group (GG) ≥2 cancer in a standardised, multi-institutional active surveillance cohort and concluded with the recommendation of systema...
“Before having a prostate cancer biopsy, I’d demand an MRI scan”
These are the words of Dr Mark Porter, in his latest column on The Times.
In addition to calling for all men with suspected prostate cancer to have access to an MRI scan as part of a better diagnostic pathway, Dr Porter also highlights the importance of the transperineal biopsy - as opposed to the traditional TRUS, or transrectal, biopsy, where the biopsy needle is...
“TREXIT 2020”: why the time to abandon transrectal prostate biopsy starts now
A new ‘Open Access’ perspective paper by Grummet, J., Gorin, M.A., Popert, R. et al. as published in Springer Nature’s Prostate Cancer and Prostatic Diseases, is calling for the full, global eradication of the transrectal (TRUS) prostate biopsy to transperineal (TP) biopsy under local anaesthetic to be instigated in 2020.
State of the Art Stokes Centre for Urology to host Two-day Uro-Oncology Masterclass covering latest Innovations in Prostate Cancer Pathway
On 20th & 21st November, Professor Stephen Langley and Dr Robert Laing will be hosting a Uro-Oncology Masterclass at the state-of-the-art Stokes Centre for Urology - a major centre for the treatment of prostate cancer both for the Surrey and Sussex Cancer Alliance and nationally.
Stephen McMahon (Queen's University Research Fellow, Queen's University Belfast)
26 July 2019
High energy proton beam therapy, an advanced form of radiotherapy, made its debut in the UK in 2018. Both the NHS and private clinics began offering this treatment in the same year, but they treated very different patient groups. While the NHS used the therapy to treat childhood cancer, private clinics began treating men with prostate c...
All men with suspected prostate cancer should be offered a specialist MRI scan when they’re referred to the hospital in England, before a biopsy.
That’s the current recommendation from the National Institute for Health and Care Excellence (NICE) in its latest guidelines.
This special type of imaging, called multiparametric (mp)MRI, combines three different scans to help build a clearer picture of what’s going on in the prostate....
Forget Brexit, it’s all about TRexit – and urology nurses are leading the way
Jonah Rusere, Advanced Nurse Practitioner for South East London Accountable Cancer Network, outlines an opportunity for urology nurses to make a difference to prostate cancer pathways.
Everyone knows that Brexit didn’t happen on the 29th March, 2019. But ‘TRexit’ did – and it’s great news for prostate cancer patients all over the country. Confused? Let...
